ELTP
ELITE PHARMACEUTICALS INC /NV/Company Information
- Company Name
- ELITE PHARMACEUTICALS INC /NV/
- CIK
- CIK0001053369
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ELTP: OTC
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ELTP
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-19
- Last sale
- 2025-10-02
- Shares purchased (TTM)
- 30,000
- Shares sold (TTM)
- 1,300,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,000
- Shares outstanding
- 1,077,236,002
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -27.78%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 39 | 30 | 21 | 27 | 22 | 11 | 8 | 10 | 8 | 7 | 6 | 9 | ||||||
| Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | - | - | - | 7 | 6 | 9 | ||||||
| Accounts Receivable Net Current | 50 | 60 | 49 | 41 | 36 | 29 | 18 | 21 | 20 | 19 | 16 | 10 | ||||||
| Inventory Net | 24 | 21 | 25 | 18 | 19 | 16 | 20 | 14 | 14 | 13 | 14 | 15 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Assets Current | 114 | 112 | 97 | 86 | 78 | 58 | 48 | 45 | 43 | 40 | 37 | 35 | ||||||
| Property Plant And Equipment Net | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 10 | 10 | 10 | ||||||
| Finite Lived Intangible Assets Net | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 6 | ||||||
| Finance Lease Right Of Use Asset | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | ||||||
| Deferred Income Tax Assets Net | 7 | 8 | 10 | 12 | 13 | 18 | 21 | 21 | 22 | 22 | 20 | 19 | ||||||
Other Assets | ||||||||||||||||||
| Restricted Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Security Deposit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Assets | 140 | 138 | 126 | 117 | 111 | 96 | 91 | 88 | 88 | 84 | 75 | 71 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 6 | 7 | 3 | 5 | 3 | 6 | 2 | 3 | 3 | 3 | 4 | ||||||
| Accrued Liabilities Current | 6 | 10 | 6 | 6 | 5 | 4 | 4 | 6 | 6 | 5 | 12 | 11 | ||||||
| Contract With Customer Liability Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Secured Debt Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Loans Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Loans Payable | - | - | - | - | - | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | 17 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 30 | 17 | 13 | 11 | 11 | 12 | 15 | 13 | 14 | 13 | 19 | 19 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Secured Long Term Debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Long Term Loans Payable | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Finance Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | - | - | ||||||
| Derivative Liabilities Noncurrent | - | 17 | 28 | 40 | 47 | 25 | 34 | 22 | 9 | 6 | 6 | 3 | ||||||
| Liabilities Noncurrent | 4 | 22 | 33 | 45 | 53 | 31 | 40 | 28 | 16 | 13 | 9 | 7 | ||||||
| Liabilities | 35 | 39 | 46 | 56 | 64 | 43 | 54 | 41 | 30 | 26 | 28 | 26 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 174 | 174 | 174 | 174 | 174 | 173 | 173 | 173 | 173 | 173 | 165 | 165 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -70 | -76 | -94 | -113 | -127 | -121 | -138 | -127 | -116 | -116 | -120 | -120 | ||||||
| Stockholders Equity | 105 | 99 | 80 | 62 | 48 | 54 | 36 | 47 | 58 | 58 | 46 | 45 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 140 | 138 | 126 | 117 | 111 | 96 | 91 | 88 | 88 | 84 | 75 | 71 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 15 | ||||||
| Finance Lease Right Of Use Asset Accumulated Amortization | 1 | 1 | 1 | 1 | - | 1 | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | 1,445 | ||||||
| Common Stock Shares Issued | 1,077 | 1,077 | 1,075 | 1,073 | 1,068 | 1,068 | 1,068 | 1,068 | 1,068 | 1,068 | 1,018 | 1,014 | ||||||
| Shares Outstanding | 1,077 | 1,077 | 1,074 | 1,073 | 1,068 | 1,068 | 1,068 | 1,068 | 1,068 | 1,068 | 1,018 | 1,014 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialELITE PHARMACEUTICALS INC /NV/ (ELTP) — SEC Financial Statements & Analysis
ELITE PHARMACEUTICALS INC /NV/ (ELTP) is a pharmaceutical preparations company, incorporated in NJ. ELITE PHARMACEUTICALS INC /NV/ trades on OTC as: ELTP. ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, ELITE PHARMACEUTICALS INC /NV/ carries a market cap of $398.58M, a P/E ratio of 7.03x, a P/B ratio of 3.80x, a P/S ratio of 2.83x, an enterprise value of $361.18M, and an EV/EBITDA multiple of 10.04x. On profitability, it posts a gross margin of 43.47%, an operating margin of 24.78%, a net margin of 40.19%, a Return on Equity (ROE) of 74.31%, a Return on Assets (ROA) of 45.15%, and a Return on Invested Capital (ROIC) of 60.60%. Per share, it reports EPS of $0.05, diluted EPS of $0.05, free cash flow per share of $0.02, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 33.72% year-over-year, net income growth of -623.97% year-over-year, and EPS growth of -619.65% year-over-year. On the balance sheet, it maintains a current ratio of 3.76x, a quick ratio of 2.94x, working capital of $84.05M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, an interest coverage ratio of 56.07x, free cash flow of $17.53M (TTM), and net debt of $-37.40M. Figures sourced from SEC EDGAR.
- Market Cap
- $398.58M
- P/E TTM
- 7.03x
- EPS TTM
- $0.05
- P/B TTM
- 3.80x
- ROE TTM
- 74.31%
- ROA TTM
- 45.15%
- Debt To Equity
- 0.33x
- Free Cash Flow TTM
- $17.53M
- Net Revenue TTM Growth 1Y
- 33.72%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ELITE PHARMACEUTICALS INC /NV/ in?
ELITE PHARMACEUTICALS INC /NV/ (ELTP) operates in the Pharmaceutical Preparations industry.
What exchange does ELTP trade on?
ELITE PHARMACEUTICALS INC /NV/ (ELTP) trades on the OTC.
Where is ELITE PHARMACEUTICALS INC /NV/ incorporated?
ELITE PHARMACEUTICALS INC /NV/ is incorporated in NJ.
When was ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s most recent SEC filing?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ELTP's market cap?
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a market capitalization of $398.58M as of 2026-06-30.
What is ELTP's P/E ratio?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month P/E ratio is 7.03x as of 2026-06-30.
What is ELTP's EPS (earnings per share)?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month EPS is $0.05 as of 2026-06-30.
What is ELTP's ROE (return on equity)?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month Return on Equity (ROE) is 74.31% as of 2026-06-30.
What is ELTP's ROA (return on assets)?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month Return on Assets (ROA) is 45.15% as of 2026-06-30.
What is ELTP's ROIC (return on invested capital)?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month Return on Invested Capital (ROIC) is 60.60% as of 2026-06-30.
What is ELTP's EV/EBITDA?
ELITE PHARMACEUTICALS INC /NV/ (ELTP)'s trailing twelve month EV/EBITDA is 10.04x as of 2026-06-30.